Article Sidebar

PDF
Date Published: 26/05/2023
Abstract Views: 322
Views PDF: 143
DOI: https://doi.org/10.51298/vmj.v526i1B.5467
Issue
Vol. 526 No. 1B (2023)
Section
Các bài báo
How to Cite
Lâm , H. D. ., & Phạm , V. T. . (2023). THE EFFICACY OF MISOPROSTOL 400MCG SUBLINGUALLY IN TREATMENT OF INCOMPLETE ABORTION AT GESTATIONAL AGE LESS THAN 9 WEEKS IN THE MEKONG HOSPITAL. Vietnam Medical Journal, 526(1B). https://doi.org/10.51298/vmj.v526i1B.5467

THE EFFICACY OF MISOPROSTOL 400MCG SUBLINGUALLY IN TREATMENT OF INCOMPLETE ABORTION AT GESTATIONAL AGE LESS THAN 9 WEEKS IN THE MEKONG HOSPITAL

Hoàng Duy Lâm 1,, Việt Thanh Phạm 2
1 Tam anh hospital
2 Mekong Obstetrics & Gynecology Hospital

Main Article Content

Abstract

Objectives: The rate success  and related factors of Misoprostol 400mcg sublingually the treatment of incomplete abortion after medical abortion at 9 weeks gestation at Mekong Hospital in 2022. Methods: A cross-sectional study surveying 120 patients diagnosed with incomplete abortion after performing medical abortion at Mekong Hospital from November 1, 2021 to November 30, 2022. Results: The success rate of misoprostol 400mcg sublingually in the treatment of STIs after medical abortion at ≤ 9 weeks gestation in the study was 103/120 (85.8%), with 95% CI [79.5]. %-92.2%]. Factors related to the results of ASD treatment with the sublingual Misoprostol 400mcg regimen: The group of patients with moderate blood volume symptoms had a success rate 2.86 times higher than the group of patients with little bleeding. OR= 2.86 (95% CI: [1.03-5.48], P = 0.04) The group of patients with a history of cesarean section had a lower success rate than the group of patients who had never had a cesarean section. (OR:0.29; 95% CI:[0.11-0.80], P = 0.01). Conclusion: This regimen is preferred for cases of incomplete abortion after medical abortion with gestational age ≤ 9 weeks.

Article Details

Keywords

Medical abortion, Incomplete miscarriage, Misoprostol

References

1. Bearak, J., et al., Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990-2019. Lancet Glob Health, 2020. 8(9): p. e1152-e1161.
2. Zeng, W.-J., et al., Expectant therapy versus curettage for retained products of conception after second trimester termination of pregnancy: analysis of outcomes and complications. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2017. 37(5): p. 569-574.
3. Nguyen Thi Nhu Ngoc, et al., Results from a study using misoprostol for management of incomplete abortion in Vietnamese hospitals: implications for task shifting. BMC pregnancy and childbirth, 2013. 13: p. 118-118.
4. Phạm Hùng Cường, Đánh giá hiệu quả của phác đồ Misoprostol 400mcg ngậm dưới lưỡi trong điều trị sẩy thai không trọn tuổi thai dưới 12 tuần tại Bệnh Viện Nhân Dân Gia Định, in Luận văn bác sĩ chuyên khoa II. 2021, Đại Học Y Dược Thành Phố Hồ Chí Minh.
5. Chow, S.C.S., J.; Wang, H,, Sample Size Calculations in Clinical Research. Marcel Dekker. New York, 2003.
6. WHO, Proposal for the inclusion of Misoprostol in the WHO model list of essential medicines. 17th Expert Committee on the Selection and Use of Essential Medicines, 2009: p. 2-20.
7. ACOG;, Misoprostol for Postabortion Care. Committee on International Affairs, 2009. 427.
8. Diop, A., et al., Two routes of administration for misoprostol in the treatment of incomplete abortion: a randomized clinical trial. Contraception, 2009. 79(6): p. 456-62.